(ICWWM Technology Centre) — In a significant development for the global tech community, Neuralink has officially announced that its ‘Blindsight’ chip is prepared to enter human clinical trials in early 2026. This pioneering technology aims to bypass traditional biological pathways by stimulating the visual cortex directly, offering hope to those who have lost their sight. Whilst ethical debates continue within the international community regarding the integration of AI and human biology, the technical achievement remains undisputed. Experts at the London Science Museum suggest that if successful, this could revolutionise how we approach sensory disabilities.
Sources: Supercar Blondie Tech
